|
|
|
|
|
|
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismRHO gene transference |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseEarly Phase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Enrolling by invitationNot Applicable Compassionate Administration of ZVS101e Injection for Extended Treatment
To provide treatment options for the control group of subjects who completed the 52-week follow-up of the Phase III clinical trial (Protocol number: ZYA-2024-001) of ZVS101e in subjects with crystalline retinal degeneration (BCD).
/ Not yet recruitingPhase 1/2 A Single-Arm, Open-Label, Phase 1/2 Clinical Trial of ZVS203e in Subjects With Retinitis Pigmentosa Associated With RHO Mutation
This trial employs a single-arm, open-label seamless Phase I/II design, consisting of two stages: Phase I dose exploration and Phase II dose expansion.The primary objective of this trial is to evaluate the safety, tolerability, and efficacy of subretinal injection of ZVS203e solution.
A Multicenter, Randomized,Controlled,Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of ZVS101e Administered as a Single Subretinal Injection in Subjects With Bietti's Crystalline Dystrophy (BCD)
This is a multi-center, randomized and controlled phase 3 clinical trial.
100 Clinical Results associated with Beijing Chigenovo Co., Ltd.
0 Patents (Medical) associated with Beijing Chigenovo Co., Ltd.
100 Deals associated with Beijing Chigenovo Co., Ltd.
100 Translational Medicine associated with Beijing Chigenovo Co., Ltd.